HIMS

Hims & Hers Health (NYSE: HIMS) rose 1% after a divided FDA advisory panel backed compounding access for...

Published: Jul 23, 2026   |  Read Original Article ↗

Article Summary

SELL
  • Hims & Hers Health (NYSE: HIMS) rose 1% after a divided FDA advisory panel backed compounding access for BPC-157, KPV, TB-500 and MOTS-C, though the recommendation is not FDA approval and still requires formal agency rulemaking.
  • Leerink Partners maintained a 'Market-Perform' rating and $25 price target, citing uncertainty around Hims' ability to build and scale a new peptide platform.
  • The brokerage estimated allowing all seven peptides being considered could create a $2.2 billion annual telehealth market with Hims potentially capturing about 20%.
  • Hims & Hers Health remains on track for a third consecutive weekly loss and its worst monthly run since February.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts. See Plans
Growth Stock Metric Rating
HIMS Rating
62.8
HOLD

Growth Stock Scoring Breakdown

METRIC VALUE WEIGHT ANALYSIS
Sales Growth TTM ? 32.8% 25% 85.0 ptsExcellent (32.8%) - Strong growth
EPS Growth Next 5Y ? 15.2% 25% 50.0 ptsMeets Minimum (15.2%) - Passes screener
Target Price Upside ? 7.2% 20% 10.0 ptsNear/At Target (7.2%) - Target: $30.38 vs Current: $32.74
Gross Margin % ? 57.5% 15% 80.0 ptsVery Healthy (57.5%) - High-quality margins
Drawdown from 52-Wk High ? -53.5% 15% 100.0 ptsDeep Discount (-53.5%) - Best entry opportunity
Disclaimer: This rating is for informational purposes only and is not financial advice. All data sourced from Finviz. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.

HIMS - Daily Chart

Loading chart data...
Powered by Finviz & ApexCharts

About HIMS

Healthcare Drug Manufacturers - Specialty & Generic 2,442 employees San Francisco, CA, United States
  • Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
  • The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
  • It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers.
  • Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services.
  • Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health.
  • The company offers its products through retail partnerships, in stores, and online.
  • Hims & Hers Health, Inc. is based in San Francisco, California.
Get BUY-rated growth stocks delivered after market close.